Biotech & Pharma

STAT+: The biotech news you need to read today

25 sec read372 views0 listens

Capricor Therapeutics is suing its Japanese partner, Nippon Shinyaku and NS Pharma, for mishandling the launch preparations of their Duchenne muscular dystrophy cell therapy. This legal battle highlights risks in biotech partnerships and could affect how developers approach collaborations and pricing strategies for new therapies. Watch for potential changes in Capricor’s market valuation and future partnership dynamics.

Read the full article at STAT Pharma


Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Views372
Ali Nemati
Ali NematiBlogUI.author_articles
BlogUI.view_profile